is this realted with crispr fixing improing singe gene disorder yes or no

Question

The phase 1 trial sponsored by Intellia Therapeutics and Regeneron Pharmaceuticals showed that lipid nanoparticles can effectively deliver genome-editing treatment systemically, leading to reductions in TTR protein levels in patient volunteers, with higher dosages resulting in greater reductions.

Answer 1

Yes